GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) es un tripeptido de union al cobre que se produce de forma natural, aislado por primera vez del plasma humano en 1973 por Loren Pickart
It was originally developed by Serono Laboratories and FDA-approved as Geref in 1997 for diagnosis and treatment of pediatric growth hormone deficiency
Lung Function Glutathione has been employed to reduce inflammation and enhance lung function in asthma, COPD, or other lung diseases
Due to concerns including potential immunogenicity, peptide aggregation, heavy metal impurity control, and copper accumulation risks, injectable GHK-Cu Copper Tripeptide-1 remains under strict regulatory control
The 75mg dose should be administered via subcutaneous injection each morning, approximately 30 minutes before the first meal of the day
noted a 73% success rate for 22 patients who underwent cystourethrectomy and Florida pouch